Coverage
Filings
| Filing | Date |
|---|---|
| Directorate Change | 27 Sept 2023 |
| GSK RSV vaccine for older adults approved in Japan | 25 Sept 2023 |
| Director/PDMR Shareholding | 21 Sept 2023 |
| Apretude for PrEP receives EMA approval | 19 Sept 2023 |
| FDA approves Ojjaara (momelotinib) | 18 Sept 2023 |
| Director/PDMR Shareholding | 13 Sept 2023 |
| Momelotinib filing accepted in Japan | 11 Sept 2023 |
| Director/PDMR Shareholding | 11 Sept 2023 |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| Director/PDMR Shareholding |
| 6 Sept 2023 |
| GSK’s Nucala CRSwNP submission accepted in Japan | 1 Sept 2023 |
| Total Voting Rights | 1 Sept 2023 |
| Holding(s) in Company | 31 Aug 2023 |